Results 51 to 60 of about 117,912 (291)
Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing. [PDF]
, 2014 Understanding genetic aberrations in cancer leads to discovery of new targets for cancer therapies. The genomic landscape of hepatocellular carcinoma (HCC) has not been fully described. Therefore, patients with refractory advanced/metastatic HCC referred
Janku, Filip +4 more
core +3 more sources
Arquivos Brasileiros de Cardiologia, 2012 FUNDAMENTO: A rápida endotelização pós-implante de stent é ocorrência desejável por teoricamente reduzir a possibilidade de trombose do stent. OBJETIVO: Avaliar a extensão da endotelização de hastes de stents eluidores de sirolimus (liberados da face ...
Celso Kiyochi Takimura +6 more
doaj +3 more sources
Stent implant follow-up in intravascular optical coherence tomography images [PDF]
, 2009 The objectives of this article are (i) to utilize computer methods in detection of stent struts imaged in vivo by optical coherence tomography (OCT) during percutaneous coronary interventions (PCI); (ii) to provide measurements for the assessment ...
Carlier, Stephane Guy +4 more
core +2 more sources
Frontiers in Pharmacology, 2021 The purposes of this study were to explore the population pharmacokinetics and initial dose optimization of sirolimus improving drug blood level for seizure control in pediatric patients with tuberous sclerosis complex (TSC).
Xiao Chen +10 more
doaj +1 more source
Repurposing metformin for cancer treatment: current clinical studies. [PDF]
, 2016 In recent years, several studies have presented evidence suggesting a potential role for metformin in anti-cancer therapy. Preclinical studies have demonstrated several anticancer molecular mechanisms of metformin including mTOR inhibition, cytotoxic ...
Altman, Jessica K +10 more
core +1 more source
mTOR inhibitor reduces nontumour-related death in liver transplantation for hepatocellular carcinoma
Molecular BiomedicineSirolimus is a regularly applied immunosuppressant for patients undergoing liver transplantation (LT) for hepatocellular carcinoma (HCC). Sirolimus not only significantly inhibits HCC recurrence but also protects renal function.
Lincheng Zhang +14 more
doaj +1 more source
Optimization of Initial Dose Regimen for Sirolimus in Pediatric Patients With Lymphangioma
Frontiers in Pharmacology, 2021 Sirolimus is an effective oral treatment for pediatric patients with lymphangioma. The present clinical study in 15 children (0.12–16.39 years of age) examines the effects of underlying factors on sirolimus concentrations through application of a ...
Xiao Chen +8 more
doaj +1 more source
A Surgical Perspective on Targeted Therapy of Hepatocellular Carcinoma. [PDF]
, 2015 Hepatocellular carcinoma (HCC), the second leading cause of cancer deaths worldwide, is difficult to treat and highly lethal. Since HCC is predominantly diagnosed in patients with cirrhosis, treatment planning must consider both the severity of liver ...
Busuttil, Ronald W +2 more
core +2 more sources
Advanced Science, EarlyView.Plasticity changes of molecular networks form a cellular learning process. Signaling network plasticity promotes cancer, metastasis, and drug resistance development. 55 plasticity‐related cancer drug targets are listed (20 having already approved drugs, 9 investigational drugs, and 26 being drug target candidates).
Márk Kerestély +5 more
wiley +1 more source